Totally dope! – A new antipsychotic mechanism of action for cannabidiol, by Anand Gururajan

The pharmacological strategy for the treatment of schizophrenia has not changed in the six decades since chlorpromazine was introduced in 1952. Although several newer agents have recently gained approval, the mechanism of action of antipsychotics is still largely based on normalising dopaminergic neurotransmission which does not adequately address the symptomatology of a very complex disorder (Hyman, 2014).  Moreover, they cause side effects such as extrapyramidal motor symptoms and metabolic syndrome which can worsen the patient condition. In this regard, preclinical and clinical studies since the ‘90s have demonstrated the antipsychotic potential of cannabidiol (CBD), a derivative of the cannabis sativa plant which does not have the adverse psychoactive properties of tetrahydrocannabinol.  In particular, CBD has been shown to be effective in attenuating the positive symptoms of schizophrenia with a negligible…


Link to Full Article: Totally dope! – A new antipsychotic mechanism of action for cannabidiol, by Anand Gururajan